World’s anti-doping labs face blood-testing hike
This article was originally published in Clinica
National authorities policing the use of performance-enhancing drugs in sport are to ensure that at least 10% of samples collected are from blood, almost trebling global average levels in 2010, under standards being introduced from 1 January 2012.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.